MacroGenics (NASDAQ:MGNX) & IM Cannabis (NASDAQ:IMCC) Head-To-Head Analysis

IM Cannabis (NASDAQ:IMCC) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for IM Cannabis and MacroGenics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
MacroGenics	1	3	1	2	2.57

MacroGenics has a consensus price target of $3.60, suggesting a potential upside of 133.77%. Given MacroGenics’ stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than IM Cannabis.

Profitability

This table compares IM Cannabis and MacroGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-9.47%	-134.35%	-11.66%
MacroGenics	-21.99%	-40.24%	-14.62%

Valuation and Earnings

This table compares IM Cannabis and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IM Cannabis	$39.44 million	0.24	-$7.72 million	($0.78)	-2.29
MacroGenics	$126.00 million	0.77	-$66.97 million	($1.20)	-1.28

IM Cannabis has higher earnings, but lower revenue than MacroGenics. IM Cannabis is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IM Cannabis has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Summary

MacroGenics beats IM Cannabis on 9 of the 15 factors compared between the two stocks.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.